Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,628
archived clinical trials in
Schizophrenia

NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
mi
from
Wards Island, NY
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
mi
from
Wards Island, NY
Click here to add this to my saved trials
Fingolimod in Schizophrenia Patients
Safety and Efficacy of Fingolimod in Schizophrenia Patients Who Have Suboptimal Responses to Antipsychotic Drug Treatment
Status: Enrolling
Updated:  10/9/2017
Center for NeuroImaging
mi
from
Indianapolis, IN
Fingolimod in Schizophrenia Patients
Safety and Efficacy of Fingolimod in Schizophrenia Patients Who Have Suboptimal Responses to Antipsychotic Drug Treatment
Status: Enrolling
Updated: 10/9/2017
Center for NeuroImaging
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Fingolimod in Schizophrenia Patients
Safety and Efficacy of Fingolimod in Schizophrenia Patients Who Have Suboptimal Responses to Antipsychotic Drug Treatment
Status: Enrolling
Updated:  10/9/2017
Prevention and Recovery Center
mi
from
Indianapolis, IN
Fingolimod in Schizophrenia Patients
Safety and Efficacy of Fingolimod in Schizophrenia Patients Who Have Suboptimal Responses to Antipsychotic Drug Treatment
Status: Enrolling
Updated: 10/9/2017
Prevention and Recovery Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Fingolimod in Schizophrenia Patients
Safety and Efficacy of Fingolimod in Schizophrenia Patients Who Have Suboptimal Responses to Antipsychotic Drug Treatment
Status: Enrolling
Updated:  10/9/2017
Larue D Carter Memorial Hospital
mi
from
Indianapolis, IN
Fingolimod in Schizophrenia Patients
Safety and Efficacy of Fingolimod in Schizophrenia Patients Who Have Suboptimal Responses to Antipsychotic Drug Treatment
Status: Enrolling
Updated: 10/9/2017
Larue D Carter Memorial Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia
Biochemical, Physiological, and Psychological Measures in Normal Controls and Relatives of Psychiatric Patients
Status: Enrolling
Updated:  10/11/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia
Biochemical, Physiological, and Psychological Measures in Normal Controls and Relatives of Psychiatric Patients
Status: Enrolling
Updated: 10/11/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
The Partners Genetics Collaborative Study of Schizophrenia
The Partners Genetics Collaborative Study of Schizophrenia
Status: Enrolling
Updated:  10/17/2017
Freedom Trail Clinic
mi
from
Boston, MA
The Partners Genetics Collaborative Study of Schizophrenia
The Partners Genetics Collaborative Study of Schizophrenia
Status: Enrolling
Updated: 10/17/2017
Freedom Trail Clinic
mi
from
Boston, MA
Click here to add this to my saved trials
Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia
Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia
Status: Enrolling
Updated:  10/19/2017
VA Greater Los Angeles
mi
from
Los Angeles, CA
Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia
Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia
Status: Enrolling
Updated: 10/19/2017
VA Greater Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors
Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors, Independent Investigator Study
Status: Enrolling
Updated:  10/24/2017
Nathan Kline Insitute for Psychiatric Research
mi
from
Orangeburg, NY
Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors
Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors, Independent Investigator Study
Status: Enrolling
Updated: 10/24/2017
Nathan Kline Insitute for Psychiatric Research
mi
from
Orangeburg, NY
Click here to add this to my saved trials
Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors
Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors, Independent Investigator Study
Status: Enrolling
Updated:  10/24/2017
Manhattan Psychatirc Center
mi
from
New York, NY
Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors
Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors, Independent Investigator Study
Status: Enrolling
Updated: 10/24/2017
Manhattan Psychatirc Center
mi
from
New York, NY
Click here to add this to my saved trials
Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors
Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors, Independent Investigator Study
Status: Enrolling
Updated:  10/24/2017
Peking University Institute of Mental Health
mi
from
Beijing,
Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors
Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors, Independent Investigator Study
Status: Enrolling
Updated: 10/24/2017
Peking University Institute of Mental Health
mi
from
Beijing,
Click here to add this to my saved trials
Vitamin D Supplementation in Psychiatric Illnesses
Effect of Vitamin D Supplementation on the Metabolic Abnormalities of Second Generation Antipsychotics in Children and Adolescents
Status: Enrolling
Updated:  11/1/2017
Univ of Massachusetts Med School
mi
from
Worcester, MA
Vitamin D Supplementation in Psychiatric Illnesses
Effect of Vitamin D Supplementation on the Metabolic Abnormalities of Second Generation Antipsychotics in Children and Adolescents
Status: Enrolling
Updated: 11/1/2017
Univ of Massachusetts Med School
mi
from
Worcester, MA
Click here to add this to my saved trials
A System for Preference Assessment in Mental Health
Implementing Patient-Centered Decision Support for Mental Health
Status: Enrolling
Updated:  11/2/2017
UCLA Center for Health Services and Society
mi
from
Los Angeles, CA
A System for Preference Assessment in Mental Health
Implementing Patient-Centered Decision Support for Mental Health
Status: Enrolling
Updated: 11/2/2017
UCLA Center for Health Services and Society
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Perceptual Deficits in Schizophrenia
Cognitive Remediation for Perceptual Deficits in Schizophrenia
Status: Enrolling
Updated:  11/3/2017
Yale University School of Medicine
mi
from
New Haven, CT
Perceptual Deficits in Schizophrenia
Cognitive Remediation for Perceptual Deficits in Schizophrenia
Status: Enrolling
Updated: 11/3/2017
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia
A Proof-of Concept Trial of Galantamine and Memantine for Cognitive Impairments in Schizophrenia: Is the Combination Effective?
Status: Enrolling
Updated:  11/6/2017
Sheppard Pratt Health System
mi
from
Baltimore, MD
Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia
A Proof-of Concept Trial of Galantamine and Memantine for Cognitive Impairments in Schizophrenia: Is the Combination Effective?
Status: Enrolling
Updated: 11/6/2017
Sheppard Pratt Health System
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment
A Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-Center Study to Assess the Antipsychotic Efficacy of ITI-007 After 6 Weeks of Treatment in Patients With Schizophrenia
Status: Enrolling
Updated:  11/8/2017
Clinical Site
mi
from
Long Beach, CA
A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment
A Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-Center Study to Assess the Antipsychotic Efficacy of ITI-007 After 6 Weeks of Treatment in Patients With Schizophrenia
Status: Enrolling
Updated: 11/8/2017
Clinical Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia
Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia Treated With Antipsychotic Medication And Potential Effects on Cognitive Function
Status: Enrolling
Updated:  11/9/2017
Nathan Kline Institute for Psychiatric Research
mi
from
New York, NY
Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia
Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia Treated With Antipsychotic Medication And Potential Effects on Cognitive Function
Status: Enrolling
Updated: 11/9/2017
Nathan Kline Institute for Psychiatric Research
mi
from
New York, NY
Click here to add this to my saved trials
Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia
Pilot Study of Pretreatment D-cycloserine for CBT-assessment of Paranoid Delusions in Schizophrenia
Status: Enrolling
Updated:  11/20/2017
MGH Schizophrenia Program - Freedom Trail Clinic
mi
from
Boston, MA
Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia
Pilot Study of Pretreatment D-cycloserine for CBT-assessment of Paranoid Delusions in Schizophrenia
Status: Enrolling
Updated: 11/20/2017
MGH Schizophrenia Program - Freedom Trail Clinic
mi
from
Boston, MA
Click here to add this to my saved trials
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
A Phase 2, Multicenter, Double-blind, Randomized, Fixed Dose, Parallel Group, 3-week Inpatient Treatment Study To Evaluate The Safety, Efficacy And Pharmacokinetics Of Pf-02545920 Compared With Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia
Status: Enrolling
Updated:  11/20/2017
California Clinical Trials Medical Group
mi
from
Glendale, CA
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
A Phase 2, Multicenter, Double-blind, Randomized, Fixed Dose, Parallel Group, 3-week Inpatient Treatment Study To Evaluate The Safety, Efficacy And Pharmacokinetics Of Pf-02545920 Compared With Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia
Status: Enrolling
Updated: 11/20/2017
California Clinical Trials Medical Group
mi
from
Glendale, CA
Click here to add this to my saved trials
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
A Phase 2, Multicenter, Double-blind, Randomized, Fixed Dose, Parallel Group, 3-week Inpatient Treatment Study To Evaluate The Safety, Efficacy And Pharmacokinetics Of Pf-02545920 Compared With Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia
Status: Enrolling
Updated:  11/20/2017
Glendale Adventist Medical Center
mi
from
Glendale, CA
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
A Phase 2, Multicenter, Double-blind, Randomized, Fixed Dose, Parallel Group, 3-week Inpatient Treatment Study To Evaluate The Safety, Efficacy And Pharmacokinetics Of Pf-02545920 Compared With Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia
Status: Enrolling
Updated: 11/20/2017
Glendale Adventist Medical Center
mi
from
Glendale, CA
Click here to add this to my saved trials
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
A Phase 2, Multicenter, Double-blind, Randomized, Fixed Dose, Parallel Group, 3-week Inpatient Treatment Study To Evaluate The Safety, Efficacy And Pharmacokinetics Of Pf-02545920 Compared With Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia
Status: Enrolling
Updated:  11/20/2017
Telecare-Cresta Loma
mi
from
Lemon Grove, CA
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
A Phase 2, Multicenter, Double-blind, Randomized, Fixed Dose, Parallel Group, 3-week Inpatient Treatment Study To Evaluate The Safety, Efficacy And Pharmacokinetics Of Pf-02545920 Compared With Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia
Status: Enrolling
Updated: 11/20/2017
Telecare-Cresta Loma
mi
from
Lemon Grove, CA
Click here to add this to my saved trials
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
A Phase 2, Multicenter, Double-blind, Randomized, Fixed Dose, Parallel Group, 3-week Inpatient Treatment Study To Evaluate The Safety, Efficacy And Pharmacokinetics Of Pf-02545920 Compared With Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia
Status: Enrolling
Updated:  11/20/2017
California Clinical Trials Medical Group
mi
from
Paramount, CA
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
A Phase 2, Multicenter, Double-blind, Randomized, Fixed Dose, Parallel Group, 3-week Inpatient Treatment Study To Evaluate The Safety, Efficacy And Pharmacokinetics Of Pf-02545920 Compared With Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia
Status: Enrolling
Updated: 11/20/2017
California Clinical Trials Medical Group
mi
from
Paramount, CA
Click here to add this to my saved trials
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
A Phase 2, Multicenter, Double-blind, Randomized, Fixed Dose, Parallel Group, 3-week Inpatient Treatment Study To Evaluate The Safety, Efficacy And Pharmacokinetics Of Pf-02545920 Compared With Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia
Status: Enrolling
Updated:  11/20/2017
LaPaz Geropsychiatric Center
mi
from
Paramount, CA
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
A Phase 2, Multicenter, Double-blind, Randomized, Fixed Dose, Parallel Group, 3-week Inpatient Treatment Study To Evaluate The Safety, Efficacy And Pharmacokinetics Of Pf-02545920 Compared With Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia
Status: Enrolling
Updated: 11/20/2017
LaPaz Geropsychiatric Center
mi
from
Paramount, CA
Click here to add this to my saved trials
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
A Phase 2, Multicenter, Double-blind, Randomized, Fixed Dose, Parallel Group, 3-week Inpatient Treatment Study To Evaluate The Safety, Efficacy And Pharmacokinetics Of Pf-02545920 Compared With Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia
Status: Enrolling
Updated:  11/20/2017
California Clinical Trials Medical Group, Inc.
mi
from
San Diego, CA
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
A Phase 2, Multicenter, Double-blind, Randomized, Fixed Dose, Parallel Group, 3-week Inpatient Treatment Study To Evaluate The Safety, Efficacy And Pharmacokinetics Of Pf-02545920 Compared With Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia
Status: Enrolling
Updated: 11/20/2017
California Clinical Trials Medical Group, Inc.
mi
from
San Diego, CA
Click here to add this to my saved trials
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
A Phase 2, Multicenter, Double-blind, Randomized, Fixed Dose, Parallel Group, 3-week Inpatient Treatment Study To Evaluate The Safety, Efficacy And Pharmacokinetics Of Pf-02545920 Compared With Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia
Status: Enrolling
Updated:  11/20/2017
Connecticut Mental Health Center-Yale University, Clinical Neuroscience Research Unit
mi
from
New Haven, CT
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
A Phase 2, Multicenter, Double-blind, Randomized, Fixed Dose, Parallel Group, 3-week Inpatient Treatment Study To Evaluate The Safety, Efficacy And Pharmacokinetics Of Pf-02545920 Compared With Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia
Status: Enrolling
Updated: 11/20/2017
Connecticut Mental Health Center-Yale University, Clinical Neuroscience Research Unit
mi
from
New Haven, CT
Click here to add this to my saved trials
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
A Phase 2, Multicenter, Double-blind, Randomized, Fixed Dose, Parallel Group, 3-week Inpatient Treatment Study To Evaluate The Safety, Efficacy And Pharmacokinetics Of Pf-02545920 Compared With Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia
Status: Enrolling
Updated:  11/20/2017
CRI Worldwide, LLC
mi
from
Willingboro, NJ
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
A Phase 2, Multicenter, Double-blind, Randomized, Fixed Dose, Parallel Group, 3-week Inpatient Treatment Study To Evaluate The Safety, Efficacy And Pharmacokinetics Of Pf-02545920 Compared With Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia
Status: Enrolling
Updated: 11/20/2017
CRI Worldwide, LLC
mi
from
Willingboro, NJ
Click here to add this to my saved trials
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
A Phase 2, Multicenter, Double-blind, Randomized, Fixed Dose, Parallel Group, 3-week Inpatient Treatment Study To Evaluate The Safety, Efficacy And Pharmacokinetics Of Pf-02545920 Compared With Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia
Status: Enrolling
Updated:  11/20/2017
St. Anthony Hospital
mi
from
Oklahoma City, OK
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
A Phase 2, Multicenter, Double-blind, Randomized, Fixed Dose, Parallel Group, 3-week Inpatient Treatment Study To Evaluate The Safety, Efficacy And Pharmacokinetics Of Pf-02545920 Compared With Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia
Status: Enrolling
Updated: 11/20/2017
St. Anthony Hospital
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
A Phase 2, Multicenter, Double-blind, Randomized, Fixed Dose, Parallel Group, 3-week Inpatient Treatment Study To Evaluate The Safety, Efficacy And Pharmacokinetics Of Pf-02545920 Compared With Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia
Status: Enrolling
Updated:  11/20/2017
IPS Research Company
mi
from
Oklahoma City, OK
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
A Phase 2, Multicenter, Double-blind, Randomized, Fixed Dose, Parallel Group, 3-week Inpatient Treatment Study To Evaluate The Safety, Efficacy And Pharmacokinetics Of Pf-02545920 Compared With Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia
Status: Enrolling
Updated: 11/20/2017
IPS Research Company
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated:  11/27/2017
Massachusetts General Hospital
mi
from
Boston, MA
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated: 11/27/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated:  11/27/2017
Touchstone innovare
mi
from
Grand Rapids, MI
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated: 11/27/2017
Touchstone innovare
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated:  11/27/2017
Community Council of Nashua
mi
from
Nashua, NH
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated: 11/27/2017
Community Council of Nashua
mi
from
Nashua, NH
Click here to add this to my saved trials
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated:  11/27/2017
University of Alabama Psychology Clinic
mi
from
Birmingham, AL
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated: 11/27/2017
University of Alabama Psychology Clinic
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated:  11/27/2017
Centerstone Research Institute
mi
from
Bloomington, IN
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated: 11/27/2017
Centerstone Research Institute
mi
from
Bloomington, IN
Click here to add this to my saved trials
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated:  11/27/2017
Massachusetts Mental Health Center
mi
from
Boston, MA
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated: 11/27/2017
Massachusetts Mental Health Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated:  11/27/2017
University of Minnesota Psychological Clinic
mi
from
Minneapolis, MN
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated: 11/27/2017
University of Minnesota Psychological Clinic
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated:  11/27/2017
West Central Behavioral Health
mi
from
Claremont, NH
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated: 11/27/2017
West Central Behavioral Health
mi
from
Claremont, NH
Click here to add this to my saved trials
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated:  11/27/2017
Riverbend Community Mental Health Center
mi
from
Concord, NH
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated: 11/27/2017
Riverbend Community Mental Health Center
mi
from
Concord, NH
Click here to add this to my saved trials
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated:  11/27/2017
Mental Health Center of Greater Manchester
mi
from
Manchester, NH
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated: 11/27/2017
Mental Health Center of Greater Manchester
mi
from
Manchester, NH
Click here to add this to my saved trials
Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal
Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal
Status: Enrolling
Updated:  11/29/2017
John Umstead Hospital
mi
from
Butner, NC
Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal
Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal
Status: Enrolling
Updated: 11/29/2017
John Umstead Hospital
mi
from
Butner, NC
Click here to add this to my saved trials
Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal
Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal
Status: Enrolling
Updated:  11/29/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal
Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal
Status: Enrolling
Updated: 11/29/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Peer Support for Increasing Physical Activity in People With Serious Mental Illnesses
Activating Consumers to Exercise in Community Psychiatry Through Peer Support
Status: Enrolling
Updated:  12/4/2017
Johns Hopkins University
mi
from
Baltimore, MD
Peer Support for Increasing Physical Activity in People With Serious Mental Illnesses
Activating Consumers to Exercise in Community Psychiatry Through Peer Support
Status: Enrolling
Updated: 12/4/2017
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Enhancing Cognitive Training Through Exercise After a First Schizophrenia Episode
Enhancing Cognitive Training Through Exercise After a First Schizophrenia Episode
Status: Enrolling
Updated:  12/5/2017
University of California at Los Angeles
mi
from
Los Angeles, CA
Enhancing Cognitive Training Through Exercise After a First Schizophrenia Episode
Enhancing Cognitive Training Through Exercise After a First Schizophrenia Episode
Status: Enrolling
Updated: 12/5/2017
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia
Sensoril® (Ashwagandha), an Immunomodulator and Anti-inflammatory Agent for Schizophrenia: A Parallel Group, Randomized Double Blind, and Placebo Controlled Study
Status: Enrolling
Updated:  12/8/2017
Western Psychiatric Institute and Clinic
mi
from
Pittsburgh, PA
Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia
Sensoril® (Ashwagandha), an Immunomodulator and Anti-inflammatory Agent for Schizophrenia: A Parallel Group, Randomized Double Blind, and Placebo Controlled Study
Status: Enrolling
Updated: 12/8/2017
Western Psychiatric Institute and Clinic
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Varenicline Adjunctive Treatment in Schizophrenia
Varenicline Adjunctive Treatment in Schizophrenia
Status: Enrolling
Updated:  12/9/2017
UMB School of Medicine
mi
from
Baltimore, MD
Varenicline Adjunctive Treatment in Schizophrenia
Varenicline Adjunctive Treatment in Schizophrenia
Status: Enrolling
Updated: 12/9/2017
UMB School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
Varenicline Adjunctive Treatment in Schizophrenia
Varenicline Adjunctive Treatment in Schizophrenia
Status: Enrolling
Updated:  12/9/2017
University of Maryland Medical System
mi
from
Baltimore, MD
Varenicline Adjunctive Treatment in Schizophrenia
Varenicline Adjunctive Treatment in Schizophrenia
Status: Enrolling
Updated: 12/9/2017
University of Maryland Medical System
mi
from
Baltimore, MD
Click here to add this to my saved trials
Varenicline Adjunctive Treatment in Schizophrenia
Varenicline Adjunctive Treatment in Schizophrenia
Status: Enrolling
Updated:  12/9/2017
Maryland Psychiatric Research Center
mi
from
Baltimore, MD
Varenicline Adjunctive Treatment in Schizophrenia
Varenicline Adjunctive Treatment in Schizophrenia
Status: Enrolling
Updated: 12/9/2017
Maryland Psychiatric Research Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
Randomised, Parallel-group, Double-blind Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Age-comparable Healthy Volunteers
Status: Enrolling
Updated:  12/18/2017
Altman Clinical and Translational Research Institute
mi
from
La Jolla, CA
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
Randomised, Parallel-group, Double-blind Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Age-comparable Healthy Volunteers
Status: Enrolling
Updated: 12/18/2017
Altman Clinical and Translational Research Institute
mi
from
La Jolla, CA
Click here to add this to my saved trials
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
Randomised, Parallel-group, Double-blind Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Age-comparable Healthy Volunteers
Status: Enrolling
Updated:  12/18/2017
Memory Enhancement Center of America, Inc.
mi
from
Eatontown, NJ
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
Randomised, Parallel-group, Double-blind Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Age-comparable Healthy Volunteers
Status: Enrolling
Updated: 12/18/2017
Memory Enhancement Center of America, Inc.
mi
from
Eatontown, NJ
Click here to add this to my saved trials
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
Randomised, Parallel-group, Double-blind Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Age-comparable Healthy Volunteers
Status: Enrolling
Updated:  12/18/2017
Community Clinical Research
mi
from
Austin, TX
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
Randomised, Parallel-group, Double-blind Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Age-comparable Healthy Volunteers
Status: Enrolling
Updated: 12/18/2017
Community Clinical Research
mi
from
Austin, TX
Click here to add this to my saved trials
Biomarker Study of Acamprosate in Schizophrenia
Biomarker Study of Acamprosate in Schizophrenia
Status: Enrolling
Updated:  12/21/2017
Maryland Psychiatric Research Center
mi
from
Baltimore, MD
Biomarker Study of Acamprosate in Schizophrenia
Biomarker Study of Acamprosate in Schizophrenia
Status: Enrolling
Updated: 12/21/2017
Maryland Psychiatric Research Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Biomarker Study of Acamprosate in Schizophrenia
Biomarker Study of Acamprosate in Schizophrenia
Status: Enrolling
Updated:  12/21/2017
Keypoint Community Mental Health Centers- Catonsville
mi
from
Baltimore, MD
Biomarker Study of Acamprosate in Schizophrenia
Biomarker Study of Acamprosate in Schizophrenia
Status: Enrolling
Updated: 12/21/2017
Keypoint Community Mental Health Centers- Catonsville
mi
from
Baltimore, MD
Click here to add this to my saved trials